

CITATION REPORT

List of articles citing

Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease

**DOI: 10.1016/s0002-9149(99)00308-2
American Journal of Cardiology, 1999, 83, 3F-12F.**

Source: <https://exaly.com/paper-pdf/30566438/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
397	Sildenafil. 1999 , 1, 137-47		16
396	Sildenafil (Viagra) and ophthalmology. 1999 , 44, 153-62		136
395	Fibrates, dyslipoproteinaemia and cardiovascular disease. 1999 , 10, 561-74		110
394	Design of a trial evaluating myocardial cell protection with cariporide, an inhibitor of the transmembrane sodium-hydrogen exchanger: the Guard During Ischemia Against Necrosis (GUARDIAN) trial. 2000 , 1, 59-67		14
393	Diltiazem-mediated inhibition of sildenafil metabolism may promote nitrate-induced hypotension. 2000 , 30, 641-2		12
392	Modern management of acute myocardial infarction. 2000 , 25, 677-782		8
391	Characterization and effects of methyl-2- (4-aminophenyl)-1, 2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5). <i>Biochemical Pharmacology</i> , 2000 , 60, 1333-41	6	41
390	Penile erection and cardiac risk: pathophysiologic and pharmacologic mechanisms. <i>American Journal of Cardiology</i> , 2000 , 86, 23F-26F	3	30
389	Cardiovascular risk and sildenafil. <i>American Journal of Cardiology</i> , 2000 , 86, 57F-61F	3	65
388	Moderate alcohol consumption is associated with decreased platelet activity in patients presenting with acute myocardial infarction. 2000 , 9, 229-34		17
387	The role of fibric acid derivatives in the secondary prevention of coronary heart disease. <i>Current Cardiology Reports</i> , 2000 , 2, 452-8	4.2	4
386	Role of LXRs in control of lipogenesis. 2000 , 14, 2831-8		1275
385	Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators. 2000 , 102, 3032-8		325
384	Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. 2000 , 102, 2997-3002		49
383	Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study. 2000 , 20, 529-37		123
382	Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. 2000 , 271, 445-50		178
381	Sex and the patient with cardiovascular risk factors: focus on sildenafil. 2000 , 109 Suppl 9A, 13S-21S; discussion 29S-30S		32

380	Garlic and onions: their effect on eicosanoid metabolism and its clinical relevance. 2000 , 62, 55-73		119
379	Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. 2000 , 70, 1327-31		33
378	Laser ablation of the prostate versus transurethral resection of the prostate in men with benign prostatic hyperplasia. 2000 , 56, 546-7		0
377	Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. 2000 , 56, 545		4
376	Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. 2000 , 56, 545-546		
375	Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. 2000 , 55, 146-50		109
374	Potential of adenosine receptor agonists for the prevention and treatment of coronary artery disease and acute myocardial infarction. 2000 , 5, 89-108		4
373	Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 25-31	15.1	146
372	Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 845-51	15.1	250
371	Leptin in nonalcoholic steatohepatitis: is it one of the hits? 2001 , 96, 2519-2520		2
370	Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 286-92	15.1	39
369	Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1981-8	15.1	19
368	Antiagregantes plaquetarios. 2001 , 8, 2823-2831		
367	Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium. 2001 , 33, 575-80		44
366	Coronary stenting and platelet glycoprotein IIb/IIIa receptor blockade in acute myocardial infarction. 2001 , 141, S26-35		4
365	Sildenafil citrate: a therapeutic update. 2001 , 23, 2-23		65
364	Inhibitors of platelet signal transduction as anti-aggregatory drugs. 2001 , 10, 865-90		28
363	Novel antipsychotics and severe hyperlipidemia. 2001 , 21, 369-74		114

362	High-density lipoprotein: epidemiology, metabolism, and antiatherogenic effects. 2001 , 47, 369-416		14
361	Comparison of the effects of dietary n-3 and n-6 polyunsaturated fatty acids on very-low-density lipoprotein secretion when delivered to hepatocytes in chylomicron remnants. 2001 , 357, 481-7		9
360	Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications. 2001 , 19, 40-5		15
359	Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients. 2001 , 31, 707-13		5
358	Evaluation of side effects of sildenafil in group of young healthy volunteers. 2001 , 32, 705-8		12
357	The effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. 2001 , 70, 270-9		49
356	Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. 2001 , 15, 707-13		77
355	Use of surrogate endpoints: a practical necessity in lipid-altering and antiatherosclerosis drug development. <i>American Journal of Cardiology</i> , 2001 , 87, 35A-41A	3	9
354	Effect of sildenafil on non-adrenergic non-cholinergic neurotransmission in bovine penile small arteries. 2001 , 412, 155-69		29
353	The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation. 2001 , 420, 55-65		43
352	Basal tonic release of nitric oxide coupled to cGMP production regulates the vascular reactivity of the mesenteric bed. 2001 , 424, 221-7		17
351	High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. 2001 , 427, 285-93		52
350	FR226807: a potent and selective phosphodiesterase type 5 inhibitor. 2001 , 428, 295-302		17
349	KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5. 2001 , 431, 17-24		13
348	Sex, the heart, and sildenafil. 2001 , 26, 388-415		4
347	Genetic control of coordinated changes in HDL and LDL size phenotypes. 2001 , 21, 1829-33		20
346	Transmural distribution of three-dimensional systolic strains in stunned myocardium. 2001 , 104, 336-41		28
345	Leptin in nonalcoholic steatohepatitis: is it one of the "hits"? 2001 , 96, 2519-20		3

344	Hemorrhoidal bleeding associated with sildenafil. 2001 , 96, 2518-9		13
343	Sildenafil inhibits hypoxia-induced pulmonary hypertension. 2001 , 104, 424-8		406
342	Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. 2001 , 15, 1718-26		204
341	Interaction of sildenafil with cAMP-mediated vasodilation in vivo. 2002 , 40, 763-7		24
340	Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. 2002 , 50, 758-64		132
339	Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. 2002 , 31, 251-3		20
338	Safe sex for men with coronary artery disease: exercise, sildenafil, and risk of cardiac events. 2002 , 287, 766-7		8
337	Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. 2002 , 283, H1263-9		218
336	The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 1232-40	15.1	238
335	Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. 2002 , 106, 1097-103		150
334	Management of Erectile Dysfunction. 2002 , 10, 431-452		5
333	T-1032, a novel phosphodiesterase type 5 inhibitor, increases the survival of cardiomyopathic hamsters. 2002 , 443, 179-84		2
332	Relaxation and cGMP formation in response to sildenafil and sodium nitroprusside in saphenous veins from normotensive and hypertensive patients. 2002 , 15, 798-802		5
331	Mechanisms of action of nitric oxide in the brain stem: role of oxidative stress. 2002 , 98, 24-7		46
330	Risk factors for cardiovascular disease in women with subclinical hypothyroidism. 2002 , 12, 421-5		160
329	Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries?. 2002 , 13, 229-46		20
328	S-Propyl-Cysteine Sulfoxide and DL-Methionine Sulfoxide Inhibit the Secretion of Apolipoprotein B100 and Lipids in HepG2 Cells. 2002 , 51, 243-250		2
327	Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta. 2002 , 440, 45-52		28

326	Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. 2002 , 456, 91-8		22
325	Inhibition of platelet P2Y12 and alpha2A receptor signaling by cGMP-dependent protein kinase. <i>Biochemical Pharmacology</i> , 2002 , 64, 433-9	6	9
324	Combination therapy in peripheral vascular disease: the rationale of using both thrombolytic and antiplatelet drugs. 2002 , 194, S103-13		3
323	S-propyl cysteine reduces the secretion of apolipoprotein B100 and triacylglycerol by HepG2 cells. 2002 , 18, 505-9		16
322	Xanthine-analog, KMUP-2, enhances cyclic GMP and K ⁺ channel activities in rabbit aorta and corpus cavernosum with associated penile erection. 2002 , 55, 162-172		2
321	Introduction. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 1S-3S	3.8	3
320	Sildenafil citrate: lessons learned from 3 years of clinical experience. 2002 , 14 Suppl 1, S43-52		59
319	Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. 2002 , 14, 178-88		25
318	Tolerability and safety profile of sildenafil citrate (Viagra) in Latin American patient populations. 2002 , 14 Suppl 2, S54-9		8
317	The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. 2002 , 22, 1124-31		99
316	KMUP-1 relaxes rabbit corpus cavernosum smooth muscle in vitro and in vivo: involvement of cyclic GMP and K(+) channels. <i>British Journal of Pharmacology</i> , 2002 , 135, 1159-66	8.6	38
315	HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins. 2003 , 17, 53-62		22
314	Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. 2003 , 26, 18-24		25
313	New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines. 2003 , 26, III19-24		24
312	Platelet anti-aggregatory effects of coumarins from the roots of <i>Angelica genuflexa</i> and <i>A. gigas</i> . 2003 , 26, 723-6		84
311	Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. 2003 , 4, 457-65		69
310	Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. 2003 , 46, 674-82		87
309	A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol is a risk factor for cardiovascular disease in subjects with abnormal glucose metabolism--The Hoorn Study. 2003 , 46, 910-6		60

308	Cycloalliin, a cyclic sulfur imino acid, reduces serum triacylglycerol in rats. 2003 , 19, 140-3		42
307	Triglycerides and HDL-cholesterol in pediatric patients. 2003 , 17, 151-158		2
306	Sildenafil in patients with cardiovascular disease. <i>American Journal of Cardiology</i> , 2003 , 92, 26M-36M	3	32
305	Overview of phosphodiesterase 5 inhibition in erectile dysfunction. <i>American Journal of Cardiology</i> , 2003 , 92, 9M-18M	3	160
304	Characterization of a novel phosphodiesterase type 5 inhibitor: JNJ-10258859. 2003 , 472, 73-80		14
303	Impact of sodium-hydrogen exchange inhibition by cariporide on death or myocardial infarction in high-risk CABG surgery patients: results of the CABG surgery cohort of the GUARDIAN study. 2003 , 126, 420-7		116
302	Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. <i>Congestive Heart Failure</i> , 2003 , 9, 9-15		27
301	Sildenafil citrate does not affect QT intervals and QT dispersion: an important observation for drug safety. 2003 , 8, 14-7		10
300	Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 209-12	3.8	24
299	Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without type 2 diabetes mellitus. 2003 , 58, 415-20		35
298	T-1032, a cyclic GMP phosphodiesterase-5 inhibitor, acutely blocks physiologic insulin-mediated muscle haemodynamic effects and glucose uptake in vivo. <i>British Journal of Pharmacology</i> , 2003 , 140, 1283-91	8.6	7
297	Effect of PDE5 inhibition combined with free oxygen radical scavenger therapy on erectile function in a diabetic animal model. 2003 , 15, 347-54		47
296	What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience. 2003 , 15, 412-7		23
295	Westernization of lifestyle markedly increases carotid intima-media wall thickness (IMT) in Japanese people. <i>Atherosclerosis</i> , 2003 , 166, 67-72	3.1	46
294	Localization of genes that control LDL size fractions in baboons. <i>Atherosclerosis</i> , 2003 , 168, 15-22	3.1	28
293	Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. 2003 , 24, 2206-12		55
292	Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. 2003 , 163, 1567-77		81
291	Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. 2003 , 108, 239-44		124

290	Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. 2003 , 101, 265-9		111
289	Should the patient with coronary artery disease use sildenafil?. 2003 , 6, 161-5		11
288	Non erectile dysfunction application of sildenafil. 2003 , 28, 325-33		10
287	Serum lipids and age-related lens opacities: a longitudinal investigation: the Framingham Studies. 2003 , 110, 578-83		36
286	The pre-existence of an acute coronary event predicts differences in biological parameters and clinical evolution among patients with longstanding stable angina. <i>International Journal of Cardiology</i> , 2003 , 91, 193-200	3.2	3
285	Physiology and pathophysiology of vascular signaling controlled by guanosine 3',5'-cyclic monophosphate-dependent protein kinase [corrected]. 2003 , 108, 2172-83		267
284	Long-term use of sildenafil. 2003 , 4, 397-405		89
283	Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. 2003 , 100, 5531-6		50
282	Phosphodiesterase type 5 (PDE5) inhibitors. 2003 , 41, 249-306		23
281	Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. 2003 , 126, 241-7		231
280	Are stenting and glycoprotein IIb/IIIa blockade of good value in primary percutaneous coronary intervention?. 2003 , 108, 2831-3		
279	Triglycerides, high-density lipoprotein cholesterol, and risk of ischemic heart disease: a view from the Copenhagen Male Study. <i>Metabolic Syndrome and Related Disorders</i> , 2003 , 1, 33-53	2.6	10
278	The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. 2003 , 55, 271-324		247
277	Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. 2003 , 64, 533-46		260
276	Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome. 2003 , 12, 133-5		31
275	CHD prevention: the importance of identifying dyslipidaemia. 2003 , 12, 950-8		
274	The effects of dietary n-3 polyunsaturated fatty acids delivered in chylomicron remnants on the transcription of genes regulating synthesis and secretion of very-low-density lipoprotein by the liver: modulation by cellular oxidative state. 2003 , 228, 143-51		29
273	Análise dos traçados de ondas da agregação plaquetária em pacientes com doenças cardiovasculares em uso do fármaco acetil salicílico comparados a doadores de sangue. 2004 , 26, 239		2

272 Heart Disease and Erectile Dysfunction. **2004,**

271 Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications. **2004, 13, 332-5**

270 The neurovascular mechanism of clitoral erection: nitric oxide and cGMP-stimulated activation of BKCa channels. **2004, 18, 1382-91** 78

269 Sleep disturbance and onset of type 2 diabetes. **2004, 27, 282-3** 182

268 Development of an assessment tool for screening children for glucose intolerance by oral glucose tolerance test. **2004, 27, 280-1** 8

267 Vitiligo associated with subcutaneous insulin lispro infusion in type 1 diabetes. **2004, 27, 275-6** 6

266 Similar A1C outcomes in type 1 diabetic patients undergoing intensive diabetes management with preprandial rapid-acting insulin and either CSII or glargine. **2004, 27, 272-3** 14

265 Aseptic peritonitis revealed through recurrent catheter obstructions in type 1 diabetic patients treated with continuous peritoneal insulin infusion. **2004, 27, 276-7** 6

264 Increased prevalence of enteroviral RNA in blood spots from newborn children who later developed type 1 diabetes: a population-based case-control study. **2004, 27, 285-6** 23

263 Physician attitudes toward foot care education and foot examination and their correlation with patient practice. **2004, 27, 286-7** 20

262 Hepatocyte growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy: its relationship with vascular endothelial growth factor and retinopathy activity. **2004, 27, 287-8** 6

261 Autoimmune hypoglycemia in a type 2 diabetic patient with anti-insulin and insulin receptor antibodies. **2004, 27, 288-9** 30

260 Primary coronary intervention for acute myocardial infarction. **2004, 291, 736-9** 38

259 Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes. **2004, 27, 273-4** 17

258 Vinegar improves insulin sensitivity to a high-carbohydrate meal in subjects with insulin resistance or type 2 diabetes. **2004, 27, 281-2** 92

257 Phenotypic Heterogeneity and Associations of Two Aldose Reductase Gene Polymorphisms With Nephropathy and Retinopathy in Type 2 Diabetes: Response to Ng et al.. **2004, 27, 290-290** 1

256 Phenotypic heterogeneity and associations of two aldose reductase gene polymorphisms with nephropathy and retinopathy in type 2 diabetes: response to Wang et al. **2004, 27, 289-90; author reply 290** 22

255 Improvement of temperature and flow in feet of subjects with diabetes with use of a transdermal preparation of L-arginine: a pilot study. **2004, 27, 284-5** 11

254	The biological variation of sex hormone-binding globulin in type 2 diabetes: implications for sex hormone-binding globulin as a surrogate marker of insulin resistance. 2004 , 27, 278-80		28
253	Plasma interleukin-18 concentrations are elevated in type 2 diabetes. 2004 , 27, 272		29
252	Comparative study of prognostic value for coronary disease risk between the U.K. prospective diabetes study and Framingham models. 2004 , 27, 277-8		35
251	Non-HDL cholesterol contributes to the "hypertriglyceridemic waist" as a cardiovascular risk factor: the Hoorn study. 2004 , 27, 283-4		35
250	Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. 2004 , 24, 63-8		30
249	Tissue expression, distribution, and regulation of PDE5. 2004 , 16 Suppl 1, S8-S10		58
248	Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. 2004 , 16 Suppl 1, S34-7		62
247	Haemodynamic effects of the selective phosphodiesterase 5 inhibitor, UK-357,903, in conscious SHR. <i>British Journal of Pharmacology</i> , 2004 , 141, 114-22	8.6	5
246	Metabolic syndrome and risk of stroke. 2004 , 6 Suppl 3, S30-4		4
245	Phosphodiesterase inhibitors in the management of primary pulmonary hypertension. 2004 , 19, 74-9		1
244	The impact of sildenafil on molecular science and sexual health. 2004 , 46, 9-14		8
243	Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. <i>American Journal of Cardiology</i> , 2004 , 94, 1475-7	3	107
242	Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. <i>Biochemical Pharmacology</i> , 2004 , 67, 1559-67	6	62
241	Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries. 2004 , 190, 1283-90		51
240	Enhanced expression of an antibody-targeted plasminogen activator in <i>Escherichia coli</i> by fusion to decorsin. 2004 , 26, 717-21		2
239	Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. 2004 , 255, 188-205		260
238	Expression of PDE5 splice variants during ontogenesis of chick dorsal root ganglia. 2004 , 78, 815-23		5
237	Plasma adiponectin and pregnancy-induced insulin resistance. 2004 , 27, 274-5		71

236	Erectile dysfunction and cardiovascular disease. 2004 , 79, 782-94		14
235	AHJ at the meetings American Heart Journal - Volume 147, Issue 4. 2004 , 147, 611-612		
234	Sildenafil. 2004 ,		
233	AHJ at the meetings. 2004 , 147, 611-612		
232	Visual short-term effects of Viagra: double-blind study in healthy young subjects. 2004 , 137, 842-9		50
231	Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction. 2004 , 17, 1040-4		38
230	Sildenafil: emerging cardiovascular indications. 2004 , 78, 1496-506		53
229	Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil. 2004 , 25, 625-9		42
228	[Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis]. 2005 , 64, 123-36		2
227	Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator. 2005 , 32, 728-34		33
226	The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5. 2005 , 17, 331-9		55
225	Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig. 2005 , 521, 105-14		22
224	Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension. <i>American Journal of Cardiology</i> , 2005 , 96, 47M-51M	3	150
223	Peroxynitrite-induced relaxation in isolated rat aortic rings and mechanisms of action. 2005 , 209, 269-76		34
222	Nitric oxide and penile erectile function. 2005 , 106, 233-66		163
221	Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. 2005 , 42, 219-32		155
220	Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil. 2005 , 164, 626-9		44
219	The effect of glycoprotein IIIa PIA 1/A2 polymorphism on the PFA-100 response to GP IIb IIIa receptor inhibitors-the importance of anticoagulants used. 2005 , 20, 57-63		11

218	Hemodynamic effects of sildenafil citrate (Viagra) on segmental branches of bilateral renal arteries. 2005 , 37, 785-9		2
217	Type 5 phosphodiesterase inhibition: the focus shifts to the heart. 2005 , 112, 2589-91		14
216	Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. 2005 , 112, 2642-9		142
215	Expression of PDE11A in normal and malignant human tissues. 2005 , 53, 895-903		48
214	Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. <i>Journal of Biological Chemistry</i> , 2005 , 280, 12944-55	5-4	272
213	Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. 2005 , 1, 283-93		34
212	Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. 2005 , 111, 742-6		113
211	Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. 2005 , 102, 1661-6		196
210	Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. 2005 , 172, 105-13		266
209	Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. 2005 , 32, 419-29, vi		34
208	Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 2550-5	5.6	124
207	Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation. 2005 , 337, 382-5		30
206	Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. 2005 , 150, 595-601		18
205	Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. 2005 , 6, 76		25
204	Cardiovascular disease morbidity and mortality in patients with type 1 diabetes mellitus : management strategies. 2005 , 4, 75-86		8
203	Bioactive S-alk(en)yl cysteine sulfoxide metabolites in the genus <i>Allium</i> : the chemistry of potential therapeutic agents. 2005 , 22, 351-68		296
202	Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure. 2006 , 15, 733-42		26
201	Estudio experimental comparativo entre una bomba centrífuga y un nuevo sistema pulsátil: valoración plaquetaria y estudio histológico tras circulación extracorpórea. 2006 , 13, 151-161		

200	Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006 , 316, 654-61	4.7	60
199	Effects of sildenafil citrate (Viagra) on renal arteries: an evaluation with Doppler ultrasound. 2006 , 77, 170-2		4
198	Hypotensive potential of sildenafil and tamsulosin during orthostasis. 2006 , 26, 667-71		6
197	Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 1471-7	15.1	17
196	Phosphodiesterase-5 inhibitors and omental and placental small artery function in normal pregnancy and pre-eclampsia. 2006 , 127, 41-9		30
195	Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits. 2006 , 40, 405-11		83
194	Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. 2006 , 98, 1259-63		136
193	Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. 2001 , 19, 369-86		141
192	Pathophysiology and treatment of diabetic erectile dysfunction. 2006 , 8, 675-84		88
191	Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension. <i>British Journal of Clinical Pharmacology</i> , 2006 , 62, 280-7	3.8	16
190	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. 2006 , 5, 689-702		366
189	LDL particle size, fat distribution and insulin resistance in obese children. 2006 , 60, 416-20		26
188	Soluble guanylate cyclase beta1-subunit expression is increased in mononuclear cells from patients with erectile dysfunction. 2006 , 18, 432-7		5
187	Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension. 2006 , 41, 593-7		31
186	Fibrate therapy in patients with metabolic syndrome and diabetes mellitus. 2006 , 8, 356-64		14
185	The emerging role for type 5 phosphodiesterase inhibition in heart failure. <i>Current Heart Failure Reports</i> , 2006 , 3, 123-8	2.8	12
184	Phosphodiesterase-5 inhibitors and their hemodynamic effects. <i>Current Hypertension Reports</i> , 2006 , 8, 345-51	4.7	23
183	Sildenafil citrate induces migration of mouse aortic endothelial cells and proteinase secretion. 2006 , 11, 402-407		1

182	Relaxant effect of sildenafil in the rabbit basilar artery. 2006 , 44, 10-6	11
181	Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. 2006 , 542, 141-7	30
180	Mechanisms of direct relaxant effect of sildenafil, tadalafil and vardenafil on corpus cavernosum. 2006 , 541, 184-90	26
179	Tubulin ligands suggest a microtubule-NADPH oxidase relationship in postischemic cardiomyocytes. 2006 , 548, 64-73	12
178	Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha. 2006 , 210, 225-35	64
177	Factors influencing regional differences in intestinal absorption of UK-343,664 in rat: possible role in dose-dependent pharmacokinetics. 2006 , 95, 435-45	9
176	Cardiovascular effects of phosphodiesterase 5 inhibitors. 2006 , 12, 3485-94	45
175	Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. 2006 , 113, 2221-8	210
174	Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. 2006 , 99, 816-28	307
173	Hypoxia converts human macrophages into triglyceride-loaded foam cells. 2006 , 26, 1871-6	125
172	Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease. 2006 , 92, 170-6	27
171	Study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters. 2006 , 46, 785-91	28
170	Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. <i>Journal of Biological Chemistry</i> , 2007 , 282, 32749-57	5.4 81
169	cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. 2007 , 100, 1569-78	255
168	Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. 2007 , 75, 390-7	29
167	Hypercholesterolemia increases myocardial oxidative and nitrosative stress thereby leading to cardiac dysfunction in apoB-100 transgenic mice. 2007 , 76, 100-9	83
166	Chronic sildenafil in men with diabetes and erectile dysfunction. 2007 , 3, 451-64	24
165	Systems Biology. 2007 ,	4

164	Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. 2007 , 56, 1025-33		186
163	Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. 2007 , 100, 489-501		74
162	Targeting liver X receptor α a new therapeutic approach to prevent atherosclerosis?. 2007 , 2, 603-607		
161	Pharmacotherapeutic decisions in menopausal women with cardiovascular risk. 2007 , 2, 197-210		1
160	Comparison of the effects of dietary saturated, mono-unsaturated and polyunsaturated fatty acids on very-low-density lipoprotein secretion when delivered to hepatocytes in chylomicron remnant-like particles. 2007 , 35, 440-1		6
159	Protection of cardiomyocyte function by propofol during simulated ischemia is associated with a direct action to reduce pro-oxidant activity. 2007 , 42, 600-8		20
158	Discovery of distinct protein profiles for polycystic ovary syndrome with and without insulin resistance by surface-enhanced laser adsorption/ionization time of flight mass spectrometry. 2007 , 88, 145-51		16
157	Association between plasma lipid parameters and APOC3 genotypes in Brazilian subjects: effect of gender, smoking and APOE genotypes. 2007 , 380, 175-81		27
156	Hypertriglyceridemia and cardiovascular risk reduction. 2007 , 29, 763-777		97
155	Modulation of aortic vascular reactivity by sex hormones in a male rat model of metabolic syndrome. <i>Life Sciences</i> , 2007 , 80, 2170-2180	6.8	21
154	Impact of lowering triglycerides on raising HDL-C in hypertriglyceridemic and non-hypertriglyceridemic subjects. <i>International Journal of Cardiology</i> , 2007 , 119, 192-5	3.2	20
153	Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. 2007 , 116, 238-48		420
152	Phosphodiesterase regulation of nitric oxide signaling. 2007 , 75, 303-14		112
151	Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. 2007 , 8, 965-74		16
150	Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. <i>British Journal of Pharmacology</i> , 2007 , 150, 567-76	8.6	42
149	Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties. 2008 , 10, 10-7		49
148	Effect of chronic administration of sildenafil on sodium retention and on the hemodynamic complications associated with liver cirrhosis in the rat. 2007 , 572, 49-56		9
147	Effect of sildenafil and rolipram on adrenergic responses in isolated human and monkey corpus cavernosum. 2007 , 52, 253-8		6

146	Structural genomics and drug discovery. 2007 , 11, 224-38		63
145	Myocardial phosphodiesterases and regulation of cardiac contractility in health and cardiac disease. 2007 , 21, 171-94		61
144	Nonurologic applications of phosphodiesterase type 5 inhibitors. 2007 , 4, 64-70		1
143	Gene expression and protein localization of calmodulin-dependent phosphodiesterase during ontogenesis of chick retina. 2008 , 86, 1017-23		3
142	Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. <i>American Journal of Cardiology</i> , 2008 , 101, 1003-8	3	82
141	Failure is an option: learning from unsuccessful proof-of-concept trials. 2008 , 13, 913-6		26
140	Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health. 2008 , 29, 3-14		39
139	The use of phosphodiesterase 5 inhibitors with concomitant medications. 2008 , 31, 799-808		49
138	An apolipoprotein A-V gene SNP is associated with marked hypertriglyceridemia among Asian-American patients. <i>Journal of Lipid Research</i> , 2008 , 49, 1846-54	6.3	48
137	FoxO1 integrates insulin signaling to VLDL production. 2008 , 7, 3162-70		99
136	Apolipoprotein AV: gene expression, physiological role in lipid metabolism and clinical relevance. 2008 , 3, 371-384		4
135	Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009 , 331, 842-50	4.7	37
134	Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. 2009 , 119, 628-47		525
133	Role of Ca ²⁺ /calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. 2009 , 105, 956-64		129
132	Genetic and environmental influences on factors associated with cardiovascular disease and the metabolic syndrome. <i>Journal of Lipid Research</i> , 2009 , 50, 1917-26	6.3	93
131	Cardiovascular effects of phosphodiesterase type 5 inhibitors. 2009 , 6, 658-74		38
130	Erectile dysfunction in diabetes mellitus. 2009 , 6, 1232-47		247
129	The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue. 2009 , 620, 78-83		29

128	Platelet cyclic guanosine monophosphate as a biomarker of phosphodiesterase type 5 inhibitor efficacy in the treatment of erectile dysfunction: a randomized placebo-controlled study. 2009 , 56, 1067-73	15
127	Phosphodiesterase inhibition in heart failure. 2009 , 14, 255-63	51
126	Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids. 2009 , 11, 71-9	26
125	Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. 2009 , 30, 1-24	45
124	The effect of sildenafil citrate (Viagra) on cerebral blood flow in patients with cerebrovascular risk factors. 2010 , 121, 370-6	18
123	Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. 2009 , 29, 274-82	76
122	Emerging concepts in the pathophysiology of type 2 diabetes mellitus. 2009 , 76, 216-26	26
121	Effects of aminoguanidine and melatonin on intestinal ischemia/reperfusion injury in rats: An assessor-blinded, controlled experimental study. 2009 , 70, 449-59	3
120	Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice. 2009 , 1791, 764-71	15
119	Suppression of VLDL secretion by cultured hepatocytes incubated with chylomicron remnants enriched in n-3 polyunsaturated fatty acids is regulated by hepatic nuclear factor-4alpha. 2009 , 1791, 1181-9	13
118	Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. 2009 , 74, 216-21	10
117	Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. 2009 , 28, 676-82	40
116	Relationship between apolipoprotein C-III concentrations and high-density lipoprotein subclass distribution. 2009 , 58, 668-74	9
115	cGMP: Generators, Effectors and Therapeutic Implications. <i>Handbook of Experimental Pharmacology</i> , 2009 ,	3.2 13
114	Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. 2010 , 3, 507-15	38
113	Cardioprotective effects of the novel Na ⁺ /H ⁺ exchanger-1 inhibitor KR-32560 in a perfused rat heart model of global ischemia and reperfusion: Involvement of the Akt-GSK-3beta cell survival pathway and antioxidant enzyme. 2010 , 33, 1241-51	6
112	Cardioprotective activity of Cladosiphon okamuranus fucoidan against isoproterenol induced myocardial infarction in rats. 2010 , 18, 52-7	66
111	Impact of triglycerides on lipid and lipoprotein biology in women. 2010 , 7, 189-205	11

110	Target profiling of a small library of phosphodiesterase 5 (PDE5) inhibitors using chemical proteomics. 2010 , 5, 1927-36		17
109	Modulating the nitric oxide - cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension. 2010 , 64, 15-22		8
108	Cardiac Depression Produced by L-Arginine and Phosphodiesterase Inhibitor on Isolated Mammalian Rabbit Heart: Function of Cyclic Guanosine Monophosphate (cGMP). 2010 , 5, 71-79		
107	A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway. 2010 , 30, 1315-24		51
106	Metabolic Syndrome and Insulin Resistance in Women With Subclinical Hypothyroidism. 2010 , 20, 29-32		3
105	Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. 2010 , 56, 977-86		215
104	Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. 2010 , 122, 88-95		78
103	cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. 2010 , 62, 525-63		677
102	Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. 2010 , 30, 239-45		98
101	Sildenafil protects epithelial cell through the inhibition of xanthine oxidase and the impairment of ROS production. 2010 , 44, 232-9		10
100	Protective effect of <i>Artemisia afra</i> Jacq. on isoproterenol-induced myocardial injury in Wistar rats. <i>Food and Chemical Toxicology</i> , 2010 , 48, 1969-72	4-7	25
99	Can serum apolipoprotein C-I demonstrate metabolic abnormality early in women with polycystic ovary syndrome?. 2010 , 94, 205-10		25
98	Longer time to peak flow predicts better arterial flow parameters on penile Doppler ultrasound. 2010 , 75, 112-6		8
97	Phosphodiesterases as Drug Targets. <i>Handbook of Experimental Pharmacology</i> , 2011 ,	3.2	20
96	Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy. <i>Handbook of Experimental Pharmacology</i> , 2011 , 323-44	3.2	24
95	Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters. <i>International Journal of Womens Health</i> , 2011 , 3, 87-97	2.8	15
94	Anti-platelet therapy: phosphodiesterase inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 634-46	3.8	182
93	Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in men. <i>Journal of Mens Health</i> , 2011 , 8, 109-118	1.2	2

92	An ex vivo standardized assay to measure human platelet cGMP. <i>Journal of Pharmacological and Toxicological Methods</i> , 2011 , 64, 164-7	1.7	9
91	Testosterone inhibits cAMP-phosphodiesterases in heart extracts from rats and increases cAMP levels in isolated left atria. <i>Pharmacology</i> , 2011 , 87, 155-60	2.3	9
90	The role of triglycerides in atherosclerosis. <i>Current Cardiology Reports</i> , 2011 , 13, 544-52	4.2	201
89	APOA5 gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerides in a Mediterranean population. <i>Journal of Nutrition</i> , 2011 , 141, 380-5	4.1	47
88	Rat skeletal muscle contractility: The role of beta-adrenoceptors and nitric oxide system. <i>Acta Veterinaria</i> , 2011 , 61, 339-348	0.9	
87	Cardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects. <i>Hormone and Metabolic Research</i> , 2012 , 44, 766-75	3.1	22
86	Design, synthesis, and pharmacological evaluation of monocyclic pyrimidinones as novel inhibitors of PDE5. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 10540-50	8.3	24
85	Docking-based CoMFA and CoMSIA analyses of tetrahydro- β -carboline derivatives as type-5 phosphodiesterase inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2012 , 27, 730-43	5.6	10
84	Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig. <i>Life Sciences</i> , 2012 , 90, 328-36	6.8	54
83	Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1921-7	15.1	58
82	Sildenafil stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells via distinct signaling pathways. <i>Biochemical Pharmacology</i> , 2012 , 84, 1045-54	6	19
81	Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. <i>Current Heart Failure Reports</i> , 2012 , 9, 192-9	2.8	26
80	Antiplatelet Agents. <i>Handbook of Experimental Pharmacology</i> , 2012 ,	3.2	4
79	Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. <i>British Journal of Pharmacology</i> , 2012 , 165, 1288-305	8.6	224
78	The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 644-9	2.3	22
77	Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. <i>Current Hypertension Reports</i> , 2013 , 15, 475-83	4.7	42
76	Reproductive sequelae of diabetes in male patients. <i>Endocrinology and Metabolism Clinics of North America</i> , 2013 , 42, 899-914	5.5	15
75	The effect of cilostazol on right heart function and pulmonary pressure. <i>Cardiovascular Therapeutics</i> , 2013 , 31, e88-93	3.3	4

74	The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies. <i>Indian Heart Journal</i> , 2013 , 65, 683-90	1.6	3
73	Acute effect of sildenafil on central hemodynamics in mechanically ventilated patients with WHO group III pulmonary hypertension and right ventricular failure necessitating administration of dobutamine. <i>International Journal of Cardiology</i> , 2013 , 167, 848-54	3.2	6
72	Acquired Disorders of Platelet Function. 2013 , 1049-1073		1
71	Proteomic and metabolomic approaches to the study of polycystic ovary syndrome. <i>Molecular and Cellular Endocrinology</i> , 2013 , 370, 65-77	4.4	39
70	Effect of quercetin-rich onion peel extracts on arterial thrombosis in rats. <i>Food and Chemical Toxicology</i> , 2013 , 57, 99-105	4.7	26
69	ATF4 protein deficiency protects against high fructose-induced hypertriglyceridemia in mice. <i>Journal of Biological Chemistry</i> , 2013 , 288, 25350-25361	5.4	74
68	Evaluation of Antidiabetic Activity and Associated Toxicity of Artemisia afra Aqueous Extract in Wistar Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2013 , 2013, 929074	2.3	29
67	The Histopathological Effect of Sildenafil Citrate on Superior Colliculus of Adult Male Rat. <i>Journal of Interdisciplinary Histopathology</i> , 2013 , 1, 175	1	2
66	Effect of sildenafil-induced nitric oxide on the histomorphology of cardiomyocytes in male rats. <i>International Journal of Applied & Basic Medical Research</i> , 2013 , 3, 84-7	1.1	14
65	Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure?. <i>Congestive Heart Failure</i> , 2013 , 19, 99-103		18
64	Physical Stress Echocardiography: Prediction of Mortality and Cardiac Events in Patients with Exercise Test showing Ischemia. <i>Arquivos Brasileiros De Cardiologia</i> , 2014 , 103, 418-425	1.2	3
63	Cardiovascular risk factors in 2011 and secular trends since 2007: the Cardiovascular Risk in Young Finns Study. <i>Scandinavian Journal of Public Health</i> , 2014 , 42, 563-71	3	53
62	Identifying pseudohypertriglyceridemia in clinical practice. <i>Clinical Lipidology</i> , 2014 , 9, 625-641		8
61	FoxO6 integrates insulin signaling with MTP for regulating VLDL production in the liver. <i>Endocrinology</i> , 2014 , 155, 1255-67	4.8	26
60	Sildenafil mediates blood-flow redistribution and neuroprotection after neonatal hypoxia-ischemia. <i>Stroke</i> , 2014 , 45, 850-6	6.7	41
59	The effects of treatment on lipoprotein subfractions evaluated by polyacrylamide gel electrophoresis in patients with autoimmune hypothyroidism and hyperthyroidism. <i>Lipids in Health and Disease</i> , 2014 , 13, 158	4.4	6
58	Sildenafil improves skeletal muscle oxygenation during exercise in men with intermittent claudication. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2014 , 307, R396-404	3.2	15
57	The effects of combined free radical scavenger and sildenafil therapy on age-associated erectile dysfunction: An animal model. <i>Urology Annals</i> , 2014 , 6, 314-20	1	7

56	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. <i>Global Cardiology Science & Practice</i> , 2014 , 2014, 257-90	0.7	10
55	Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism in the Setting of Type 2 Diabetes. <i>Contemporary Diabetes</i> , 2014 , 55-99	0	
54	Lipoprotein lipase gene sequencing and plasma lipid profile. <i>Journal of Lipid Research</i> , 2014 , 55, 85-93	6.3	15
53	Role of inorganic nitrate and nitrite in driving nitric oxide-cGMP-mediated inhibition of platelet aggregation in vitro and in vivo. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 1880-9	15.4	49
52	Sildenafil alters retinal function in mouse carriers of retinitis pigmentosa. <i>Experimental Eye Research</i> , 2014 , 128, 43-56	3.7	23
51	Understanding of chest pain in microvascular disease proved by cardiac magnetic resonance image (UMPIRE): study protocol for a randomized controlled trial. <i>Trials</i> , 2014 , 15, 333	2.8	6
50	Physical activity on endothelial and erectile dysfunction: a literature review. <i>Aging Male</i> , 2014 , 17, 125-30.	3.1	35
49	Sildenafil vaginal suppositories: preparation, characterization, in vitro and in vivo evaluation. <i>Drug Development and Industrial Pharmacy</i> , 2014 , 40, 803-12	3.6	14
48	Modulation of diabetes and dyslipidemia in diabetic insulin-resistant rats by mangiferin: role of adiponectin and TNF- α . <i>Anais Da Academia Brasileira De Ciencias</i> , 2014 , 86, 1935-48	1.4	44
47	A comprehensive review of erectile dysfunction in men with diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2015 , 123, 141-58	2.3	47
46	Effect of sildenafil on platelet function and platelet cGMP of patients with erectile dysfunction. <i>Andrologia</i> , 2015 , 47, 1098-102	2.4	3
45	PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. <i>Pharmacology & Therapeutics</i> , 2015 , 147, 12-21	13.9	144
44	Erectile Dysfunction in Hypertension and Cardiovascular Disease. 2015 ,		2
43	Acute and Subchronic Oral Toxicity Evaluation of Aqueous Root Extract of <i>Dicoma anomala</i> Sond. in Wistar Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016 , 2016, 3509323	2.3	14
42	Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model. <i>Biomedicine and Pharmacotherapy</i> , 2016 , 81, 136-144	7.5	11
41	Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2016 , 291, 14695-705	5.4	6
40	Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016 , 356, 341-53	4.7	38
39	FoxO1: A Conductor of Insulin Signaling to Glucose and Lipid Metabolism. 2016 , 79-99		

38	Structure-activity and in vivo evaluation of a novel lipoprotein lipase (LPL) activator. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017 , 27, 303-308	2.9	12
37	Triglycerides Revisited to the Serial. <i>Advances in Clinical Chemistry</i> , 2017 , 80, 1-44	5.8	3
36	Retrospective study of tadalafil for fetal growth restriction: Impact on maternal and perinatal outcomes. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017 , 43, 291-297	1.9	17
35	Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 6622-6637	8.3	23
34	Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy. <i>Orphanet Journal of Rare Diseases</i> , 2017 , 12, 100	4.2	15
33	Determinants of low levels of brain natriuretic peptide in morbid obesity. <i>Clinical Nutrition</i> , 2017 , 36, 1075-1081	5.9	10
32	Developing a Modified Low-Density Lipoprotein (M-LDL-C) Friedewald's Equation as a Substitute for Direct LDL-C Measure in a Ghanaian Population: A Comparative Study. <i>Journal of Lipids</i> , 2018 , 2018, 7078409	2.7	11
31	Antidiabetic and Safety Properties of Ethanolic Leaf Extract of <i>Corchorus olitorius</i> in Alloxan-Induced Diabetic Rats. 2018 ,		3
30	Endothelial colony forming cells from human umbilical cord blood improved severe erectile dysfunction in obese type II diabetic rats. <i>Life Sciences</i> , 2018 , 207, 272-283	6.8	3
29	Cardiovascular Safety of Phosphodiesterase Type 5 Inhibitors After Nearly 2 Decades on the Market. <i>Sexual Medicine Reviews</i> , 2018 , 6, 583-594	5.6	14
28	Protective action of aqueous leaf extract of <i>Gazania krebsiana</i> (Less.) Asteraceae antagonizes isoproterenol-triggered myocardial infarction in <i>Rattus norvegicus</i> . <i>Comparative Clinical Pathology</i> , 2018 , 27, 461-470	0.9	2
27	Oxidative Stress in Response to Saturated Fat Ingestion Is Linked to Insulin Resistance and Hyperandrogenism in Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5360-5371	5.6	18
26	Physical Activity, Exercise, and Lipids and Lipoproteins. 2019 , 265-293		1
25	Saturated Fat Ingestion Promotes Lipopolysaccharide-Mediated Inflammation and Insulin Resistance in Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 934-946	5.6	28
24	Sildenafil does not reliably improve exercise performance in hypoxia: a systematic review. <i>BMJ Open Sport and Exercise Medicine</i> , 2019 , 5, e000526	3.4	2
23	In Silico Mapping of Essential Residues in the Catalytic Domain of PDE5 Responsible for Stabilization of Its Commercial Inhibitors. <i>Scientia Pharmaceutica</i> , 2019 , 87, 29	4.3	
22	cGMP Signaling in Cardiovascular Diseases: Linking Genotype and Phenotype. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 75, 516-525	3.1	6
21	Inflammation Triggered by Saturated Fat Ingestion Is Linked to Insulin Resistance and Hyperandrogenism in Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	18

20	Associations Between the Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Metabolic Syndrome, Insulin Resistance, and Lifestyle Habits in Healthy Japanese. <i>Metabolic Syndrome and Related Disorders</i> , 2020 , 18, 260-266	2.6	11
19	Lipid-induced mononuclear cell cytokine secretion in the development of metabolic aberration and androgen excess in polycystic ovary syndrome. <i>Human Reproduction</i> , 2020 , 35, 1168-1177	5.7	3
18	Novel antiplatelet targets in the treatment of acute coronary syndromes. <i>Platelets</i> , 2021 , 32, 15-28	3.6	7
17	Triglyceride-lowering LPL alleles combined with LDL-C-lowering alleles are associated with an additively improved lipoprotein profile. <i>Atherosclerosis</i> , 2021 , 328, 144-152	3.1	2
16	The Contribution of Triglycerides and Triglyceride-Rich Lipoproteins to Atherosclerotic Cardiovascular Disease. 2011 , 230-251		1
15	Continuous Metabolic Syndrome Scores for Children Using Salivary Biomarkers. <i>PLoS ONE</i> , 2015 , 10, e0138979	13	13
14	Common Variants in 6 Lipid-Related Genes Discovered by High-Resolution DNA Melting Analysis and Their Association with Plasma Lipids. <i>Journal of Clinical & Experimental Cardiology</i> , 2011 , 2,	0	6
13	Effects of Tocols Rich Fraction Isolated from Rice Bran Oil Deodorizer Distillate on Plasma and Hepatic Lipid Concentrations in Rats. <i>Journal of Biosciences and Medicines</i> , 2015 , 03, 1-8	0.2	2
12	Association between Prostaglandin-endoperoxide Synthase 2 (PTGS2) Polymorphisms and Blood Pressure in Korean Population. <i>Genomics and Informatics</i> , 2008 , 6, 110-116	1.9	3
11	Saturated fat ingestion stimulates proatherogenic inflammation in polycystic ovary syndrome. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021 , 321, E689-E701	6	2
10	Hyperlipidemias and Nutrient-Gene Interactions. 2001 ,		
9	Bedside Platelet Monitoring. 2004 , 495-520		
8	Hyperlipidemias. 2007 , 715-726		
7	Carotid Artery Intima-Media Thickness in Young Adults with Family History of Coronary Artery Disease. <i>Journal of Clinical and Diagnostic Research JC DR</i> , 2015 , 9, CC01-4	0	1
6	A STUDY OF FASTING AND POSTPRANDIAL LIPID ABNORMALITIES IN TYPE 2 DIABETES MELLITUS. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2016 , 5, 4234-4238	0.1	
5	MAIN CHARACTERISTICS OF LIPID AND CARBOHYDRATE METABOLISM OBSERVED IN YOUNG MALES WITH DIFFERENT SOMATOTYPES OF NORTHEAST RUSSIA. <i>Ekologiya Cheloveka (Human Ecology)</i> , 2017 , 40-44	2.1	1
4	Lipid-carbohydrate metabolism and nutrition in the indigenous and non-indigenous population of the north-east of Russia. <i>Klinicheskaia Meditsina</i> , 2018 , 96, 544-551	0.2	1
3	The Amniotic Fluid Proteome Differs Significantly between Donor and Recipient Fetuses in Pregnancies Complicated by Twin-to-Twin Transfusion Syndrome. <i>Journal of Korean Medical Science</i> , 2020 , 35, e73	4.7	1

2	Toxicological profile of the aqueous-fermented extract of in rats. <i>Avicenna Journal of Phytomedicine</i> , 2018 , 8, 478-487	1.4	4
1	Seaweed sulfated polysaccharides and their medicinal properties. 2022 , 68, 102885		1